Literature DB >> 24224771

DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.

Jerome Moreaux1, Angelique Bruyer, Jean-Luc Veyrune, Hartmut Goldschmidt, Dirk Hose, Bernard Klein.   

Abstract

Entities:  

Keywords:  drug sensitivity prediction; epigenetics; gene arrays; gene expression; myeloma

Mesh：

Substances：

Year:  2013        PMID： 24224771      PMCID： PMC5104837          DOI： 10.1111/bjh.12660

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Authors:  Jérôme Moreaux; Bernard Klein; Régis Bataille; Géraldine Descamps; Sophie Maïga; Dirk Hose; Hartmut Goldschmidt; Anna Jauch; Thierry Rème; Michel Jourdan; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

2.  Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Authors:  Dirk Hose; Thierry Rème; Thomas Hielscher; Jérôme Moreaux; Tobias Messner; Anja Seckinger; Axel Benner; John D Shaughnessy; Bart Barlogie; Yiming Zhou; Jens Hillengass; Uta Bertsch; Kai Neben; Thomas Möhler; Jean François Rossi; Anna Jauch; Bernard Klein; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

3.  Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Laura Chiecchio; Emma M Smith; Kevin D Boyd; Antonino Neri; Faith E Davies; Fiona M Ross; Gareth J Morgan
Journal:  Blood       Date:  2010-10-13       Impact factor: 22.113

4.  A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.

Authors:  Paul W Hollenbach; Aaron N Nguyen; Helen Brady; Michelle Williams; Yuhong Ning; Normand Richard; Leslie Krushel; Sharon L Aukerman; Carla Heise; Kyle J MacBeth
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

5.  Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.

Authors:  Christoph J Heuck; Jayesh Mehta; Tushar Bhagat; Krishna Gundabolu; Yiting Yu; Shahper Khan; Grigoris Chrysofakis; Carolina Schinke; Joseph Tariman; Eric Vickrey; Natalie Pulliam; Sangeeta Nischal; Li Zhou; Sanchari Bhattacharyya; Richard Meagher; Caroline Hu; Shahina Maqbool; Masako Suzuki; Samir Parekh; Frederic Reu; Ulrich Steidl; John Greally; Amit Verma; Seema B Singhal
Journal:  J Immunol       Date:  2013-02-13       Impact factor: 5.422

6.  Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

Authors:  Martin F Kaiser; David C Johnson; Ping Wu; Brian A Walker; Annamaria Brioli; Fabio Mirabella; Christopher P Wardell; Lorenzo Melchor; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

Review 7.  The potential role of epigenetic therapy in multiple myeloma.

Authors:  Emma M Smith; Kevin Boyd; Faith E Davies
Journal:  Br J Haematol       Date:  2009-11-13       Impact factor: 6.998

8.  Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.

Authors:  Jérôme Moreaux; Thierry Rème; Wim Leonard; Jean-Luc Veyrune; Guilhem Requirand; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  Mol Cancer Ther       Date:  2012-10-18       Impact factor: 6.261

9.  Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

Authors:  Metin Karahoca; Richard L Momparler
Journal:  Clin Epigenetics       Date:  2013-02-01       Impact factor: 6.551

10.  Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.

Authors:  Ken Maes; Eline Menu; Els Van Valckenborgh; Ivan Van Riet; Karin Vanderkerken; Elke De Bruyne
Journal:  Cancers (Basel)       Date:  2013-04-15       Impact factor: 6.639
  10 in total
  9 in total

Review 1.  Methodological challenges in constructing DNA methylation risk scores.

Authors:  Anke Hüls; Darina Czamara
Journal:  Epigenetics       Date:  2019-07-22       Impact factor: 4.528

Review 2.  Seeking Convergence and Cure with New Myeloma Therapies.

Authors:  Priya Choudhry; Derek Galligan; Arun P Wiita
Journal:  Trends Cancer       Date:  2018-06-27

3.  In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Authors:  Ken Maes; Eva De Smedt; Alboukadel Kassambara; Dirk Hose; Anja Seckinger; Els Van Valckenborgh; Eline Menu; Bernard Klein; Karin Vanderkerken; Jérôme Moreaux; Elke De Bruyne
Journal:  Oncotarget       Date:  2015-02-20

4.  RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.

Authors:  E Viziteu; B Klein; J Basbous; Y-L Lin; C Hirtz; C Gourzones; L Tiers; A Bruyer; L Vincent; C Grandmougin; A Seckinger; H Goldschmidt; A Constantinou; P Pasero; D Hose; J Moreaux
Journal:  Leukemia       Date:  2017-02-10       Impact factor: 11.528

5.  Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.

Authors:  Veronika Vikova; Michel Jourdan; Nicolas Robert; Guilhem Requirand; Stéphanie Boireau; Angélique Bruyer; Laure Vincent; Guillaume Cartron; Bernard Klein; Olivier Elemento; Alboukadel Kassambara; Jérôme Moreaux
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556

6.  Genetic and environment effects on structural neuroimaging endophenotype for bipolar disorder: a novel molecular approach.

Authors:  Bo Hu; Jungwon Cha; Janice M Fullerton; Sonia Hesam-Shariati; Kunio Nakamura; John I Nurnberger; Amit Anand
Journal:  Transl Psychiatry       Date:  2022-04-04       Impact factor: 6.222

Review 7.  Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?

Authors:  Catharina Muylaert; Lien Ann Van Hemelrijck; Anke Maes; Kim De Veirman; Eline Menu; Karin Vanderkerken; Elke De Bruyne
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

8.  The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS.

Authors:  Satoko Oka; Kazuo Ono; Masaharu Nohgawa
Journal:  Am J Hematol       Date:  2018-08-06       Impact factor: 10.047

Review 9.  Multiple Myeloma: Heterogeneous in Every Way.

Authors:  Anaïs Schavgoulidze; Titouan Cazaubiel; Aurore Perrot; Hervé Avet-Loiseau; Jill Corre
Journal:  Cancers (Basel)       Date:  2021-03-13       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.